PRA Health Sciences
PRA Health Sciences Named International Clinical Research Company of the Year
RALEIGH, N.C., May 22, 2017 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc., (PRA) (NASDAQ:PRAH) is pleased to announce that for the fourth consecutive year it was recognized as the International Clinical Research Company of the Year. PRA received the award at a PharmaTimes ceremony in London. This award follows PRA's recent recognition as Clinical Research Company of the Year in the PharmaTimes Americas competition.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/29ac9b83-70bf-451e-a05f-bda1b8a05df8
"PRA is honored to once again receive this prestigious award," said David Passov, Senior Vice President, Project Management EAPA. "It is recognition of our talented and dedicated employees and their passion to help others through their clinical development work."
PRA won a total of three Gold, four Silver and five Bronze awards. Individual gold award recipients include:
- Clinical Trial Administrator of the Year: James Battisti
- Project Manager of the Year: Caroline Cattelin
Organized by PharmaTimes, the annual International Clinical Researcher of the Year competition provides a unique opportunity for clinical researchers from all over the world to benchmark their competencies and skills against their peers in an international learning environment. Designed and judged by an independent steering committee of high-level industry leaders, the International Clinical Researcher of the Year has categories for clinical researchers and teams at all stages of their career.
ABOUT PRA HEALTH SCIENCES
PRA (NASDAQ: PRAH) is one of the world's leading global CROs by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA's global clinical development platform includes more than 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East and over 13,300 employees worldwide. Since 2000, PRA has performed approximately 3,500 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 70 drugs. To learn more about PRA, please visit www.prahs.com .
MEDIA INQUIRIES: Christine Rogers, Manager - Public Relations, Corporate Communications
EMAIL: firstname.lastname@example.org PHONE: +1 919.786.8463
INVESTOR INQUIRIES: InvestorRelations.prahs.com
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Nasdaq OMX
Telix Pharmaceuticals Limited24.10.2017 01:02 | pressemeddelelse
Telix Pharmaceuticals and ANMI Partner for Prostate Cancer Imaging
Telix Pharmaceuticals Limited23.10.2017 23:02 | pressemeddelelse
Telix Pharmaceuticals Limited Launches $50 Million Underwritten Initial Public Offering (ASX: TLX)
Brookfield Asset Management Inc23.10.2017 17:05 | pressemeddelelse
Brookfield Asset Management Notice of 2017 Q3 Results Conference Call and Webcast
Rapid Micro Biosystems23.10.2017 13:02 | pressemeddelelse
Rapid Micro Biosystems Awarded a Contract by Biomedical Advanced Research and Development Authority (BARDA) for the Implementation of a Rapid Sterility Test for Vaccines
Xehar23.10.2017 12:01 | pressemeddelelse
Xehar Fashion App Ditches the Shopping Cart and Picks Up Speed
BroadSoft, Inc.23.10.2017 07:32 | pressemeddelelse
BroadSoft Hospitality Enhanced with Mobile UC-One Workstream Collaboration Capabilities to Amplify Productivity and Guest Experiences
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum